The coming of age of engineered multivalent antibodies

Drug Discovery Today

Volumn 20, Issue 5, 2015, Pages 588-594

  Nuñez Prado, Natalia ^a   Compte, Marta ^a   Harwood, Seandean ^b   Álvarez Méndez, Ana ^c   Lykkemark, Simon ^b   Sanz, Laura ^a   Álvarez Vallina, Luis ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY;

ANIMAL; ANTIBODY SPECIFICITY; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; DRUG DISCOVERY; EPITOPES; HUMANS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84937759650     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.02.013     Document Type: Review

References (82)

1. L. Sanz Antibody engineering: facing new challenges in cancer therapy Acta Pharmacol. Sin. 26 2005 641 648
2. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725
3. L. Sanz Antibodies and gene therapy: teaching old 'magic bullets' new tricks Trends Immunol. 25 2004 85 91
4. J.M. Reichert Antibodies to watch in 2014: mid-year update MAbs 6 2014 799 802
5. A.M. Scott Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
6. P. Chames Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 157 2009 220 233
7. J.M. Reichert, and E. Dhimolea The future of antibodies as cancer drugs Drug Discov. Today 17 2012 954 963
8. F. Nimmeejahn, and J.V. Ravetch Fc receptors as regulators of immunity Adv. Immunol. 96 2007 179 204
9. X.R. Jiang Advances in the assessment and control of the effector functions of therapeutic antibodies Nat. Rev. Drug Discov. 10 2011 101 111
10. R.E. Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
11. A. Beck Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins Curr. Pharm. Biotechnol. 9 2008 482 501
12. R.A. Beckman Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors Cancer 109 2007 170 179
13. A.M. Cuesta Multivalent antibodies: when design surpasses evolution Trends Biotechnol. 28 2010 355 362
14. R.E. Kontermann Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22 2011 868 876
15. J. Löfblom Non-immunoglobulin based protein scaffolds Curr. Opin. Biotechnol. 22 2011 843 848
16. S. Banta Replacing antibodies: engineering new binding proteins Annu. Rev. Biomed. Eng. 15 2010 93 113
17. S.L. Li Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth Cancer Immunol. Immunother. 49 2000 243 252
18. S. Hu Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts Cancer Res. 56 1996 3055 3061
19. O. Steifert The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity Protein Eng. Des. Sel. 25 2012 603 612
20. O. Steifert Tetravalent antibody-scTRAIL fusion proteins with improved properties Mol. Cancer Ther. 13 2014 101 111
21. M. Giersberg Covalent dimerization of camelidae anti-human TNF-alpha single domain antibodies by the constant kappa light chain domain improves neutralizing activity Biotechnol. Bioeng. 106 2010 161 166
22. S. Miethe Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library MAbs 6 2014 446 459
23. S. Yoon Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts J. Cancer Res. Clin. Oncol. 140 2014 227 233
24. L. Wan Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris Appl. Microbiol. Biotechnol. 97 2013 3855 3860
25. J.W. Jong Generation of 1E8 single chain Fv-Fc construct against human CD59 Immune Netw. 12 2012 33 39
26. P.R. Johnson Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys Nat. Med. 15 2009 901 906
27. A.P. West Jr. Single-chain Fv-based anti-HIV proteins: potential and limitations J. Virol. 86 2012 195 202
28. J.V. Leyton Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Clin. Cancer Res. 14 2008 7488 7496
29. E.J. Lepin An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors Eur. J. Nucl. Med. Mol. Imaging 37 2010 1529 1538
30. S.M. Knowles Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody J. Nucl. Med. 55 2014 452 459
31. T. Olafsen Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas J. Nucl. Med. 50 2009 1500 1508
32. R. Tavaré Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo Proc. Natl. Acad. Sci. U. S. A. 21 2014 1108 1113
33. T. Han Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma PLOS ONE 7 2012 e44455
34. E. Li Mammalian cell expression of dimeric small immune proteins (SIP) Protein Eng. 10 1997 731 736
35. M. Furuta Construction of mono- and bivalent human single-chain Fv fragments against the D antigen in the Rh blood group: multimerization effect on cell agglutination and application to blood typing Protein Eng. 11 1998 233 241
36. L.S. Shahied Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format J. Biol. Chem. 279 2004 53907 53914
37. P. Holliger, and P.J. Hudson Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 23 2005 1126 1136
38. T. De Meyer Nanobody-based products as research and diagnostic tools Trends Biotechnol. 32 2014 263 270
39. P. Holliger 'Diabodies': small bivalent and bispecific antibody fragments Proc. Natl. Acad. Sci. U. S. A. 90 1993 6444 6448
40. P. Iliades Triabodies: single chain Fv fragments without a linker form trivalent trimers FEBS Lett. 409 1997 437 441
41. A. Todorovska Design and application of diabodies, triabodies and tetrabodies for cancer targeting J. Immunol. Methods 248 2001 47 66
42. J.A. Carmichael The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility J. Mol. Biol. 326 2003 341 351
43. S.M. Kipriyanov Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics J. Mol. Biol. 293 1999 41 56
44. T. Völkel Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies Protein Eng. 14 2001 815 823
45. P.A. Moore Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma Blood 117 2011 4542 4551
46. D. Neri, and R. Bicknell Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446
47. N. Pasche, and D. Neri Immunocytokines: a novel class of potent armed antibodies Drug Discov. Today 17 2012 583 590
48. T. List, and D. Neri Immunocytokines: a review of molecules in clinical development for cancer therapy Clin. Pharmacol. 20 2013 29 45
49. D. Müller, and R.E. Kontermann Recombinant bispecific antibodies for cellular cancer immunotherapy Curr. Opin. Mol. Ther. 9 2007 319 326
50. U. Reusch A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells MAbs 6 2014 728 739
51. B. Cochlovius Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation Cancer Res. 60 2000 4336 4341
52. M. Gruber Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli J. Immunol. 152 1994 5368 5374
53. M. Mack A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc. Natl. Acad. Sci. U. S. A. 92 1995 7021 7025
54. E. Wolf BiTEs: bispecific antibody constructs with unique anti-tumor activity Drug Discov. Today 10 2005 1237 1244
55. S.R. Frankel, and P.A. Baeuerle Targeting T cells to tumor cells using bispecific antibodies Curr. Opin. Chem. Biol. 17 2013 385 392
56. R. Bargou Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 2008 974 977
57. A. Goel Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application Cancer Res. 60 2000 6964 6971
58. 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: novel imaging agents for rapid in vivo localization of human colon carcinoma J. Nucl. Med. 42 2001 1519 1527
59. K. Els Conrath Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs J. Biol. Chem. 276 2001 7346 7350
60. S.M. Deyev Design of multivalent complexes using the barnase∗barstar module Nat. Biotechnol. 21 2003 1486 1492
61. H.C. Spång Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells PLOS ONE 7 2012 e45393
62. C. Halin Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor-alpha Cancer Res. 63 2003 3202 3210
63. L. Borsi Selective targeted delivery of TNF-alpha to tumor blood vessels Blood 102 2003 4384 4392
64. E. Balza Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin Clin. Cancer Res. 12 2006 2575 2582
65. S.M. Kipriyanov Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen Hum. Antibod. Hybrid. 6 1995 93 101
66. S.M. Deyev, and E.N. Lebedenko Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design Bioessays 30 2008 904 918
67. V.J. Sánchez-Arévalo Lobo Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events Int. J. Cancer 119 2006 455 462
68. A.M. Cuesta In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences PLoS ONE 4 2009 e5381
69. A.M. Cuesta Improved stability of multivalent antibodies containing the human collagen XV trimerization domain MAbs 4 2012 226 232
70. D. Sánchez-Martín The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies J. Biol. Chem. 286 2011 5197 5203
71. A. Blanco-Toribio Generation and characterization of monospecific and bispecific hexavalent trimerbodies MAbs 5 2013 1 10
72. C.Y. Fan Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold FASEB J. 22 2008 3795 3804
73. E.A. Rossi Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting Proc. Natl. Acad. Sci. U. S. A. 103 2006 6841 6846
74. E.A. Rossi Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 113 2009 6161 6171
75. D.L. Rossi A new class of bispecific antibodies to redirect T cells for cancer immunotherapy MAbs 6 2014 381 391
76. J. Zhang Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents J. Mol. Biol. 335 2004 49 56
77. E. Stone The assembly of single domain antibodies into bispecific decavalent molecules J. Immunol. Methods 318 2007 88 94
78. P. Pack, and A. Pluckthun Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli Biochemistry 31 1992 1579 1584
79. R. Schoonjans Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives J. Immunol. 165 2000 7050 7057
80. R. Schoonjans A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain Biomol. Eng. 17 2001 193 202
81. D. Lu Di-diabody: a novel tetravalent bispecific antibody molecule by design J. Immunol. Methods 279 2003 219 232
82. P. Pack Tetravalent miniantibodies with high avidity assembling in Escherichia coli J. Mol. Biol. 246 1995 28 34